scholarly journals Leukocyte profile in cord blood of newborns to diabetic and non-diabetic mothers

2021 ◽  
Vol 9 (6) ◽  
pp. 1662
Author(s):  
Nazima Thaseen ◽  
Shivakumar Veeraiah
Keyword(s):  
Stem Cells ◽  
Immune System ◽  
Cord Blood ◽  
Cell Count ◽  
Interleukin 6 ◽  
Interleukin 1 ◽  
Statistical Treatment ◽  
Diabetic Mother ◽  
Glycemic Status ◽  
Diabetic Mothers

Background: Increasing incidence of diabetes due to strees inducing life-style, involves dearrangement of carbohydrate, fat, protein metabolism characterized by hyperglycemia, hyperlipidimia and negative nitrogen balance respectively. Causing morbidity and mortality, effects gestational diabetes. Pregnancy, capacity to secrete insulin increases with gestational age, has effect in last trimester of pregnancy. Maternal glycemic-status influences neonates leucocyte profile.Methods: Fully automated haematology analyzer ABXMICROsot used to analyze cord blood of neonates born to 40 diabetic (known to be diabetic at pregnancy) and 40 non-diabetic mothers, collected in EDTA tubes. Diabetic group was sub divided into D1 and D2. D1 as 100-150 mg/dcl, D2 as above 150 mg/dcl. Statistical treatment of Levene's test of equality of variances applied to the data.Results: WBC count, granulocyte percent and monocyte percent were significantly lower, lymphocyte percent was higher in neonates to diabetic mothers. Significantly higher in D2 then D1group. The prognosis for the child of a pregnant diabetic is related to the degree of control of mother’s glycemic status, reflected higher indices in D2 then D1.Conclusions: Neonates immune system depends on the mother's immune system i.e.; immunological properties are practically under control of interleukin-1 and interleukin-6. Interleukin-6 potentiates action of interleukin-1 synergistically, such action of interleukin converts non-committed stem cells to committed stem cells. Immunosuppressant status in diabetic mother (i.e.; non-priming of neonatal interleukin-6 by immunosuppressant diabetic mother’s interleukin-6, main cause for altered counts) modulating neonatal interleukin-6 it decreases haematopoietic potential in the neonates, ECF in infants of diabetic mother is reduced leading to haemo-concentration, increasing cell count. Pictures as increase cell count at birth in neonates of diabetic mother.

scholarly journals Erythrocyte profile in cordblood of newborns to diabetic and non-diabetic mothers

2021 ◽  
Vol 9 (2) ◽  
pp. 449
Author(s):  
Nazima Thaseen ◽  
Shivakumar Veeraiah
Keyword(s):  
Stem Cells ◽  
Immune System ◽  
Interleukin 6 ◽  
Interleukin 1 ◽  
Hemoglobin Concentration ◽  
Diabetic Mother ◽  
Mean Corpuscular Hemoglobin ◽  
Corpuscular Hemoglobin ◽  
Cell Counts ◽  
Diabetic Mothers

Background: Diabetes, an endocrinal disorder causing morbidity and mortality has its effect on gestational diabetes. Intrapartum stress, maternal hyperglycemia leads to fetal hyperglycemia. The maternal glycaemic status has influence on neonates erythrocyte profile.Methods: Cord blood of neonates born to 40 diabetic (known to be diabetic at pregnancy) and 40 non-diabetic mothers were selected. A fully automated hematology analyzer ABXMICROsot was used to analyze whole blood collected in EDTA tubes. The diabetic group was subdivided into D1 and D2. D1 as 100-150 mg/dcl, D2 as above 150 mg/dcl.Results: Hemoglobin, hematocrit, MCV, MCH, RDW were significantly higher, RBC count were comparatively insignificant. Hemoglobin (Hb), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), Mean corpuscular hemoglobin concentration (MCHC) were significantly higher in D2 than D1 group. The prognosis for the child of a pregnant diabetic is related to the degree of control of mother’s glycemic status, reflected as higher indices in D2 than D1.Conclusions: Neonatal immune system depends on maternal immune system i.e, all the immunological properties are practically under the control of interleukin-1 and interleukin-6. Interleukin-6 potentiates the action of interleukin-1 synergistically, such action of interleukin converts noncommitted stem cells to committed stem cells. Immunosuppressant status in diabetic mother (i.e., non-priming of neonatal interleukin-6 by immunosuppressant diabetic mother`s interleukin-6, the main cause for these altered count). By modulating neonatal interleukin-6 it decreases hematopoietic potential in the neonates, on the other hand ECF in infants of diabetic mother is reduced leading to hemoconcentration and increase in cell counts. Giving a picture as if polycythemia at birth in neonates of diabetic mothers.  

Interleukin-1, Interleukin-6: Messengers in the Neuroendocrine Immune System?

1991 ◽  
Vol 187 (5) ◽  
pp. 622-625 ◽  
Author(s):  
E. Hooghe-Peters ◽  
B. Velkeniers ◽  
L. Vanhaelst ◽  
R. Hooghe
Keyword(s):  
Immune System ◽  
Interleukin 6 ◽  
Interleukin 1

scholarly journals Synergistic factors for stem cell proliferation: further studies of the target stem cells and the mechanism of stimulation by interleukin-1, interleukin-6, and granulocyte colony-stimulating factor

Blood ◽  
1988 ◽  
Vol 72 (6) ◽  
pp. 2007-2014 ◽  
Author(s):  
K Ikebuchi ◽  
JN Ihle ◽  
Y Hirai ◽  
GG Wong ◽  
SC Clark ◽  
...  
Keyword(s):  
Stem Cells ◽  
Interleukin 6 ◽  
Interleukin 1 ◽  
Blast Cell ◽  
Host Responses ◽  
Colony Development ◽  
Common Mechanism ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Stimulating Factor

Serial observations of blast cell colony development from spleen cells of mice treated with 5-fluorouracil (5-FU) four days earlier revealed that either form of human interleukin-1 (IL-1 alpha or IL-1 beta) hastens the emergence of interleukin-3 (IL-3)-dependent blast cell colonies. This activity was essentially indistinguishable from the effect of interleukin-6 (IL-6) or granulocyte colony-stimulating factor (G-CSF) in the same system, an effect that we have ascribed previously to a shortening of the G0 period of the dormant stem cells. We also analyzed the time courses of colony formation from cultures of day-2 post-5-FU marrow cells supported by IL-1 alpha, IL-6, or G-CSF alone or in combination with IL-3. In the presence of IL-3, G-CSF and IL-6 but not IL-1 alpha hastened the development of colonies and increased the numbers of multilineage colonies relative to cultures of IL-3 alone. This observation, together with our previous data from the human system, suggests that the synergistic effect of IL-1 is likely due to induction of secondary growth factors, including IL-6 and G-CSF, by accessory cells in culture. The effect of IL-6 on G0 was confirmed by analysis of the cycling status of progenitor cells in short-term culture. While neither IL-3 nor IL-6 alone had any effect on the cycling status, the combination of factors resulted in a rapid recruitment of quiescent cells into cell cycle (within 48 hours) as represented by a twofold increase in the numbers of multipotential progenitors and a significant increase in the sensitivity of these cells to 3H-thymidine with high specific activity. Combinational testing of all of these synergistic factors revealed that the target cell populations for the IL-1, IL-6, and G-CSF overlap considerably, suggesting that they all may act through a common mechanism. This is further supported by our finding that cells from blast cell colonies grown in the presence of a combination of any one of the synergistic factors with IL-3 replate with higher efficiency and yield more multilineage secondary colonies than those from colonies grown in IL-3 alone. These findings provide further evidence that IL-1, IL-6, and G- CSF serve to integrate the immediate host responses to infection through augmentation of effector cells and antibody production as well as the longer term host responses by recruitment of dormant hemopoietic stem cells into active cell cycling.

Cord Blood Units Collected with Liquid CPD Appear to Contain Significantly More Nucleated and CD34+ Cells Than Units Collected with Dry Heparin.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 4227-4227 ◽  
Author(s):  
Morey Kraus ◽  
Karen Foster ◽  
Asimena Rigas Bridges ◽  
Mark C. Walters
Keyword(s):  
Stem Cells ◽  
Cord Blood ◽  
Cell Count ◽  
Cell Metabolism ◽  
Live Cells ◽  
Blood Collection ◽  
Advisory Committees ◽  
Blood Unit ◽  
Cd34 Cells ◽  
Cord Blood Unit

Abstract Abstract 4227 Transplantation of Cord Blood Stem Cells depends primarily on the number and potency of stem cells harvested, processed and cryopreserved. Previous studies have not compared the anti-coagulant used in collection systems with respect to their impact on the cord blood unit cell count and composition. We compared cord blood units collected in Citric Phosphate with Dextrose Buffer (CPD) or Heparin by measuring the pre-processed total nucleated cell count (TNC), post-processed TNC, % CD34 and total number of CD34+ cell numbers from units harvested randomly in remote hospitals in the US. Between August 2005 and May 2009, cord blood units harvested in collection bags containing lyophilized (dry) Heparin (N=65) and cord blood units harvested in FDA approved Sentinel collection bags containing 35 ml of CPD (N>6300) were processed using standard processing methods which included either RBC depletion or volume reduction based on initial collected volume. We observed significantly greater pre-processed TNC count (9.59 +/- 5.98 × 108 Vs 7.36 +/- 4.96 × 108, p=0.003), post-processing TNC count (7.72 +/- 4.61 × 108 Vs 5.80 +/- 3.63 × 108, p=0.001), % CD34+ (0.46 +/- 0.28 Vs 0.37 +/- 0.23, p=0.024) and number of CD34+ cells (2.72 +/- 2.73 × 106 Vs 1.72 +/- 1.44 × 106, p=0.003) in the CPD units. Interestingly, viability by dye exclusion was 7% higher (p=0.0001) in the post-processed Heparin units despite more pre-TNC (by 24%), post-TNCs (by 29%), and more %CD34+ (by 22%) and CD34+ cells (by 54%) in the CPD units. Post-processed CD34+ measurements relied upon gating to select live cells (by 7AAD exclusion) and reflect a decrease in viable CD34+ cells in Heparin units. Together, these results indicate that units collected using CPD contain significantly more TNCs prior to and after processing than units collected using Heparin. Furthermore, both the % CD34+ and total number of CD34+ cells were significantly lower in the Heparin containing units. Both TNC and CD34+ values are primary indicators of graft potency in clinical studies. Cord blood units collected in the pubic cord blood system and the vast majority of cord blood units used in clinical transplantation have been collected in CPD. CPD is both an anti-coagulant and a preservative as it contains Dextrose which provides a substrate for glycolysis and preserves the metabolism in cells. Heparin, which does not contain Dextrose to preserve cell metabolism, is rarely used as an anti-coagulant for blood collection, as it can only be useful for blood that is to be transfused within 12 hours of collection because it is broken down over longer periods of time. Also, the use of dry Heparin may adversely affect the osmolarity of the cord blood unit, thereby compromising cellularity. However, further studies are recommended to elucidate the mechanism by which dry Heparin may adversely affect the TNC and CD34 content of cord blood units. Disclosures: Kraus: PerkinElmer/Viacord: Employment. Foster:PerkinElmer/Viacord: Employment. Bridges:PerkinElmer/Viacord: Employment. Walters:PerkinElmer/Viacord: Membership on an entity's Board of Directors or advisory committees.

Expansion of Umbilical Cord Blood Hematopoietic Stem Cells for Clinical Use.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4049-4049
Author(s):  
Rowayda Peters ◽  
Gregor Hutter ◽  
Adriano Aguzzi ◽  
Mathias Heikenwaelder ◽  
Christoph Renner ◽  
...  
Keyword(s):  
Stem Cells ◽  
Hematopoietic Stem Cells ◽  
Cord Blood ◽  
Cell Count ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Induction Medium ◽  
Adherent Cells ◽  
Hematopoietic Stem

Abstract Umbilical cord blood (UCB) is an alternative donor source for allogeneic hematopoietic stem cell transplantation. However, transplantation in adults is frequently limited by the small number of cells available in a unit. We have previously developed the technology to expand hematopoietic stem cells (HSC) and stromal/mesenchymal stem cells (SMSC) from all UCB frozen samples (13, 3). The incubation of thawed UCB mononuclear cells (MNC) in the presence of SCF (25ng/ml), FLt-3 (25ng/ml), MGDF (10ng/ml) & IL-6 (20ng/ml) and 10% human serum in stroma-free liquid culture not only generated long term expansion of transplantable UCB HSC (non-adherent). Also, long-term expansion of SMSC (adherent cells) was successful. In order to upscale the expansion to use for clinical applications, we analyzed 3 frozen UCB comparing the expansion from 24-well plates (previous) versus expansion in bags (VueLife™) after 10 and 14 days of culture. Results show substantial expansion in total cell count (TCC, 4.8, 10.9: 2.4, 3.8 fold) at d10 and d14 from wells & bags respectively. TCC increased further in the presence of SMSC (38% & 33% in CD34+ cell count cultured in wells). CD133+CD34+CD38- HSC multiplied (11, 25 fold, d10/d14 & colony forming cells (CFC) 19 fold at d14 bags respectively). Heterogeneous cell populations were detected after d 14 in bags: T and B -lymphoid (%CD3/%CD19; 65/4:50w/3), megakaryocytic (%CD61; 7:4) and myeloid (%CD33; 31:43) at d0/d14 respectively. Further, expanded cells (250,000) containing a small number of CD133+CD34+CD38- (15,000–30,000) were injected into the liver of sub-lethally irradiated newborn Balb/C Rag2-Cγ−/− mice. Our preliminary data show no engraftment from cells expanded in wells and bags after 6 weeks of transplantation from d10 cultures (human CD45 + <1%). However, positive engraftment in mouse PB was detected from cells expanded for 14 d (wells, 1.16–2.5% & bags, 1.21–3.9%) as compared to control mice (CD45; 30% PB & 70% BM) receiving selected CD34 + (300,000 CD34+ at d0). Primitive repopulating cells (PRC), and multilineage human CFC were detected after transplantation. On d14 of HSC expansion, UCB MNC derived adherent cells (SMSC) were enriched by trypsinization. SMSC were established in serum free and serum plus culture as well. The immunophenotype of harvested SMSC was CD29+, CD44+ and CD45−, CD34− and CD133− at percentages + >90%. Following repeated trypsinization, SMSC count increased 41–96 folds. CFU-Fibroblast colonies (92–173) were generated from 104 SMSC after 2 weeks in MesenCult medium. We have previously differentiated SMSC into hepatocytes. Now we also generated adipocytes in an induction medium containing, Insulin, dexamethasone & indomethacin. SMSC formed Oil-droplet vacuoles in the cytoplasm in 3 weeks. The culture conditions we defined to maintain UCB PRC should be developed clinically. SMSC described herein exhibit in vitro properties of multipotent stem cells.

Synergism between interleukin-6 and interleukin-3 in supporting proliferation of human hematopoietic stem cells: comparison with interleukin-1 alpha

Blood ◽  
1988 ◽  
Vol 71 (6) ◽  
pp. 1759-1763 ◽  
Author(s):  
AG Leary ◽  
K Ikebuchi ◽  
Y Hirai ◽  
GG Wong ◽  
YC Yang ◽  
...  
Keyword(s):  
Stem Cells ◽  
Hematopoietic Stem Cells ◽  
Interleukin 6 ◽  
Colony Formation ◽  
Interleukin 1 ◽  
Blast Cell ◽  
Hematopoietic Stem ◽  
Interleukin 3 ◽  
The Individual ◽  
Cell Colony

Currently available evidence suggests that in the steady state, the majority of hematopoietic stem cells are dormant in cell cycle and reside in the so-called G0 period. Studies in our laboratory indicated that once a stem cell leaves G0, its subsequent proliferation requires the presence of interleukin-3 (IL-3). Recently it was reported that interleukin-1 (IL-1) may stimulate stem cells to become sensitive to IL- 3. In a separate study, we observed that interleukin-6 (IL-6, also known as B cell stimulatory factor-2/interferon beta 2) possesses synergism with IL-3, shortening the G0 period of murine hematopoietic stem cells. We report here that human IL-6 and IL-3 act synergistically in support of the proliferation of progenitors for human blast cell colonies and that IL-1 alpha reveals no synergism with IL-3 when tested against purified human marrow progenitors. Panned My-10+ human marrow cells were plated in culture and on day 14 of incubation, either IL-3, IL-6, IL-1 alpha or a combination of these factors was added to the cultures. Blast cell colony formation was analyzed daily between days 18 and 32 of culture. IL-6 or IL-1 alpha alone failed to support blast cell colony formation. In the presence of IL-3 alone, blast cell colonies continued to emerge between days 21 and 27. When a combination of IL-3 and IL-6 was added, blast cell colonies developed earlier than in cultures with IL-3 alone and twice as many blast cell colonies were identified. IL-1 alpha failed to augment IL-3-dependent blast cell colony formation. Replating studies of the individual blast cell colonies revealed various types of single as well as multilineage colonies. These observations suggest that IL-6 shortens the G0 period of human hematopoietic stem cells and that the reported synergistic activities of IL-1 on primitive hematopoietic cells may be indirect.

scholarly journals Synergism between interleukin-6 and interleukin-3 in supporting proliferation of human hematopoietic stem cells: comparison with interleukin-1 alpha

Blood ◽  
1988 ◽  
Vol 71 (6) ◽  
pp. 1759-1763 ◽  
Author(s):  
AG Leary ◽  
K Ikebuchi ◽  
Y Hirai ◽  
GG Wong ◽  
YC Yang ◽  
...  
Keyword(s):  
Stem Cells ◽  
Hematopoietic Stem Cells ◽  
Interleukin 6 ◽  
Colony Formation ◽  
Interleukin 1 ◽  
Blast Cell ◽  
Hematopoietic Stem ◽  
Interleukin 3 ◽  
The Individual ◽  
Cell Colony

Abstract Currently available evidence suggests that in the steady state, the majority of hematopoietic stem cells are dormant in cell cycle and reside in the so-called G0 period. Studies in our laboratory indicated that once a stem cell leaves G0, its subsequent proliferation requires the presence of interleukin-3 (IL-3). Recently it was reported that interleukin-1 (IL-1) may stimulate stem cells to become sensitive to IL- 3. In a separate study, we observed that interleukin-6 (IL-6, also known as B cell stimulatory factor-2/interferon beta 2) possesses synergism with IL-3, shortening the G0 period of murine hematopoietic stem cells. We report here that human IL-6 and IL-3 act synergistically in support of the proliferation of progenitors for human blast cell colonies and that IL-1 alpha reveals no synergism with IL-3 when tested against purified human marrow progenitors. Panned My-10+ human marrow cells were plated in culture and on day 14 of incubation, either IL-3, IL-6, IL-1 alpha or a combination of these factors was added to the cultures. Blast cell colony formation was analyzed daily between days 18 and 32 of culture. IL-6 or IL-1 alpha alone failed to support blast cell colony formation. In the presence of IL-3 alone, blast cell colonies continued to emerge between days 21 and 27. When a combination of IL-3 and IL-6 was added, blast cell colonies developed earlier than in cultures with IL-3 alone and twice as many blast cell colonies were identified. IL-1 alpha failed to augment IL-3-dependent blast cell colony formation. Replating studies of the individual blast cell colonies revealed various types of single as well as multilineage colonies. These observations suggest that IL-6 shortens the G0 period of human hematopoietic stem cells and that the reported synergistic activities of IL-1 on primitive hematopoietic cells may be indirect.

Sign in / Sign up

Export Citation Format

Share Document